{
    "clinical_study": {
        "@rank": "38593", 
        "acronym": "ETA1", 
        "arm_group": [
            {
                "arm_group_label": "Aerobic training", 
                "arm_group_type": "Active Comparator", 
                "description": "the intervention will be  an aerobic training program.  For the TG subjects, breathing exercises will have duration of 30 minutes and  will be  always followed by aerobic training sessions that  will  consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months."
            }, 
            {
                "arm_group_label": "Breathing exercise", 
                "arm_group_type": "Sham Comparator", 
                "description": "Patients from the control group will be  taught breathing exercises  with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest ."
            }
        ], 
        "brief_summary": {
            "textblock": "Exercise training has been proposed as adjunctive therapy in asthma to improve many clinical\n      outcomes; however its effects on bronchial hyperresponsiveness (BHR) and inflammation,\n      characteristic features in asthma, remains poorly understood. We aim to investigate the\n      effects of aerobic training on BHR (primary aim) and systemic inflammation (secondary aim).\n      In addition, clinical control and health related quality of life (HRQoL) will be  also\n      assessed."
        }, 
        "brief_title": "Effect of Aerobic Training in Moderate or Severe Asthmatic Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma.", 
        "condition_browse": {
            "mesh_term": [
                "Asthma", 
                "Inflammation", 
                "Bronchial Hyperreactivity"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, controlled and single-blind trial whose intervention will be  an\n      aerobic training. Fifty -eight patients with moderate or severe persistent asthma will be\n      recruited at a university hospital and  randomly assigned in two groups: control (CG) or\n      training (TG) .The  study will be performed  between two medical visits with intervals of\n      six months and  during  this period the same medication dosage will be maintained. Patients\n      in CG will perform (an educational program + breathing exercise; n=28) and TG patients will\n      perform (an educational program+breathing exercises+aerobic training; n=30).The sessions\n      will be conducted twice a week, for 3 months.  Before and after the intervention, all\n      patients will be evaluated by  bronchial hyperresponsiveness, serum cytokines levels, total\n      immunoglobulin E, induced sputum, fractional exhaled nitric oxide (FeNO), asthma clinical\n      control (daily symptoms dairy, exacerbations and asthma control questionnaire - ACQ), health\n      related quality of life (HRQoL); asthma quality of life questionnaire-(AQLQ), pulmonary\n      function and cardiopulmonary exercise testing. All the patients will be evaluated by\n      specific immunoglobulin E (atopy) through (skin prick test or Phadiatop)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with moderate and severe persistent asthma\n\n          -  Asthma will diagnosed according to Global Initiative for Asthma (GINA)\n\n          -  Body Mass Index <35 kg/ m2\n\n          -  Patients will submitted the  medical treatment, followed by pulmonary specialists\n             for at least 6 months.\n\n        Patients will considered  clinically stable (i.e., no exacerbation or changes in\n        medication for at least 30 days).\n\n        Exclusion Criteria:\n\n          -  Patients  will diagnosed with cardiovascular, musculoskeletal or other chronic lung\n             diseases;\n\n          -  Patients  with current participation in exercise programs\n\n          -  current smokers or ex-smokers will excluded from the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "59 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033122", 
            "org_study_id": "ETA1"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aerobic training", 
                "description": "the intervention will be  an aerobic training program.  For the TG subjects, breathing exercises will have duration of 30 minutes and  will be  always followed by aerobic training sessions that  will  consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.", 
                "intervention_name": "Aerobic training", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "Aerobic training", 
                    "Breathing exercise"
                ], 
                "description": "Patients from the control group will be  taught breathing exercises  with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .", 
                "intervention_name": "Breathing exercise", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "exercise,  bronchial hyperresponsiveness,  inflammation", 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "contact": {
                "email": "pbianchi@usp.br", 
                "last_name": "Pedro Giavina-Bianchi, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "S\u00e3o Paulo", 
                    "country": "Brazil"
                }, 
                "name": "Hospital das Cl\u00ednicas da FMUSP"
            }, 
            "investigator": [
                {
                    "last_name": "Pedro Giavina-Bianchi, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Andrezza Fran\u00e7a-Pinto, PT", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Felipe AR Mendes", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Rosana C Agondi", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Alberto Cukier", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Rafael Stelmach", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Beatriz M Saraiva-Romanholo, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Milton A Martins, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jorge Kalil, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Celso RF Carvalho, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Regina M Carvalho-Pinto", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effect of Aerobic Training on Bronchial Hyperresponsiveness and Systemic Inflammation in Patients With Moderate or Severe Asthma: a Randomized Controlled Trial", 
        "other_outcome": [
            {
                "description": "Clinical control will be   evaluated by daily symptoms dairy , exacerbation and asthma control questionnaire (ACQ) and", 
                "measure": "Clinical control", 
                "safety_issue": "No", 
                "time_frame": "before and after 3 months of intervention"
            }, 
            {
                "description": "Health related quality of life will be  assessed by the Asthma Quality Life Questionnaire (AQLQ) .", 
                "measure": "Health related quality of life", 
                "safety_issue": "No", 
                "time_frame": "before and  after 3 months of interventions"
            }
        ], 
        "overall_contact": {
            "email": "pbianchi@usp.br", 
            "last_name": "Pedro Giavina-Bianchi, MD, PhD", 
            "phone": "(11) 2661-0000", 
            "phone_ext": "6225"
        }, 
        "overall_official": {
            "affiliation": "Univeristy of S\u00e3o Paulo", 
            "last_name": "Pedro Giavina-Bianchi, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Brazil: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The bronchial provocation test will be  conducted according to American Thoracic Society (ATS) guideline (1999). Patients will inhale increasing concentrations of histamine following the sequences: 0.0625, 0.25, 1.0, 4.0 and 16.0 mg/ ml using the method of the dosimeter (DeVilbiss 646nebulizer, DeVilbiss Health Care,  USA) . Forced expiratory volume in one second (FEV1) will be measured after 30 and 90 seconds from the end of inhalations. The test will  considered positive when the concentration of histamine promotes a fall \u2265 20% in FEV1 (PC20) with respect to the post-saline value or when the maximum concentration is reached (16 mg/mL).", 
            "measure": "Bronchial hyperresponsiveness", 
            "safety_issue": "Yes", 
            "time_frame": "Before and after 3 months of intervetion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033122"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The plasma levels of inflammatory mediators will be evaluated before and after 3 months of intervention.The method Cytometric Beat Array (CBA) (BD Biosciences,  USA) will be used to analyze the levels of interleukins (IL)  IL-4, IL-5, IL-6, IL-8, IL -10, Tumor Necrosis Factor (TNF-\u03b1) and IL-12p70 and chemokines IL-8, Monocyte Chemotactic Protein-1 (MCP-1/CCL2) and RANTES", 
            "measure": "serum cytokines levels", 
            "safety_issue": "No", 
            "time_frame": "Before and after  3 months of intervention"
        }, 
        "source": "Instituto de Investiga\u00e7\u00e3o em Imunologia", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "University of Sao Paulo", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Instituto de Investiga\u00e7\u00e3o em Imunologia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}